SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (384)2/1/2002 5:28:03 PM
From: scaram(o)uche  Respond to of 724
 
For 2002, Fisher expects revenue growth, excluding foreign-exchange effects, of approximately 11 percent to 12 percent, and operating margins, reflecting the accounting changes described above, in the 7.5 percent to 7.8 percent range versus 7.3 percent in 2001.

Their strategy -- acquisitions to improve margin -- appears to be working.

In a sweet spot for growth (IMO), I suspect that Fisher will have investment capital virtually thrown at them.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News